Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave
Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis
R. Jiménez-Puya
, J.C. Moreno
Autor para correspondencia
Servicio de Dermatología. Hospital Universitario Reina Sofía. Córdoba. España
Leído
5014
Vecesse ha leído el artículo
2083
Total PDF
2931
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0001731012700042" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70004-2" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70004" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:16-24" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1703 "formatos" => array:2 [ "HTML" => 1283 "PDF" => 420 ] ] "itemSiguiente" => array:18 [ "pii" => "S0001731012700054" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70005-4" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70005" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:25-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1163 "formatos" => array:2 [ "HTML" => 621 "PDF" => 542 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab. Análisis de efectos adversos infecciosos" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "25" "paginaFinal" => "30" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab. Analysis of Rates of Infection" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Herranz-Pinto, E. Sendagorta" "autores" => array:2 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Herranz-Pinto" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Sendagorta" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700054?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731012700030" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70003-0" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70003" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:7-15" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2317 "formatos" => array:2 [ "HTML" => 1150 "PDF" => 1167 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Mecanismo de acción de ustekinumab y su relevancia en la patogénesis de la psoriasis. Impacto en el sistema inmune" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "7" "paginaFinal" => "15" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Mechanism of Action of Ustekinumab and its Relevance in the Pathogenesisof Psoriasis. Impact on the Immune System" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.M. Carrascosa" "autores" => array:1 [ 0 => array:2 [ "nombre" => "J.M." "apellidos" => "Carrascosa" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700030?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700030/v1_201304241722/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "16" "paginaFinal" => "24" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Jiménez-Puya, J.C. Moreno" "autores" => array:2 [ 0 => array:4 [ "nombre" => "R." "apellidos" => "Jiménez-Puya" "email" => array:1 [ 0 => "rjjimenez@uco.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología. Hospital Universitario Reina Sofía. Córdoba. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec85086" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "IL-12" 3 => "IL-23" 4 => "Subunidad p40" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec85085" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "IL 12" 3 => "IL-23" 4 => "p40 subunit" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El avance en el conocimiento de la fisiopatología de la psoriasis ha permitido producir nuevas terapias más eficaces y seguras en el manejo de la enfermedad, primero con el bloqueo del factor de necrosis tumoral α y, posteriormente, de forma más específica el de la vía interleucina 12/23. Las interleucinas 12 y 23 desempeñan un importante rol en la cascada inmunitaria de la psoriasis, compartiendo la subunidad proteica p40 que permite bloquear ambas citocinas, actuando de forma más concreta en la producción de la placa inflamatoria.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La eficacia de ustekinumab se ha contrastado en diversos ensayos clínicos en fase III (PHOENIX 1 y 2), y su desarrollo clínico abarca el mayor número de pacientes estudiado con un agente biológico, siendo también el único en compararse de forma <span class="elsevierStyleItalic">head to head</span> con etanercept, un agente bloqueante del factor de necrosis tumoral α (estudio ACCEPT).</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Improved understanding of the pathophysiology of psoriasis has led to the development of biologic agents that offer improved safety and efficacy in the treatment of this disease. TNF inhibitors were the first biologics to be added to the therapeutic arsenal, and these were followed by agents that selectively block IL-12 and IL-23, two cytokines that play an important role in the immune cascade that leads to psoriasis. By targeting the p40 subunit shared by these cytokines, ustekinumab blocks the activity of IL 12/23, thereby reducing skin inflammation.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The efficacy of ustekinumab has been analyzed in phase III clinical trials (PHOENIX 1 and 2) and its clinical development program was the largest ever for a biologic agent. Ustekinumab has also been compared to the TNF inhibitor etanercept in the first-ever head-to-head comparison of biologic agents in psoriasis (the ACCEPT psoriasis trial).</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.P. Schön" 1 => "W.H. Boehncke" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra041320" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "352" "paginaInicial" => "1899" "paginaFinal" => "1912" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15872205" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674910015666" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New IL-12-family members: IL-23 and IL-17 cytokines with divergent functions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C.A. Hunter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nri1648" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2005" "volumen" => "5" "paginaInicial" => "521" "paginaFinal" => "531" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15999093" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab: a new option in psoriasis therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.L. Chien" 1 => "J.T. Elder" 2 => "C.N. Ellis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2009" "volumen" => "69" "paginaInicial" => "1141" "paginaFinal" => "1152" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19537833" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 1 study investigators" "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "A.B. Kimball" 2 => "K.A. Papp" 3 => "N. Yeilding" 4 => "C. Guzzo" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60725-4" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486739" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674910019445" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 2 study investigators" "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "R.G. Langley" 2 => "M. Lebwohl" 3 => "G.G. Krueger" 4 => "P. Szapary" 5 => "N. Yeilding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60726-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1675" "paginaFinal" => "1684" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486740" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Lebwohl" 1 => "N. Yeilding" 2 => "P. Szapary" 3 => "Y. Wang" 4 => "S. Li" 5 => "Y. Zhu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.11.012" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2010" "volumen" => "63" "paginaInicial" => "571" "paginaFinal" => "579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20599293" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ustekunimab SPC [consultado 11/02/2009]. Disponible en: <a id="ir0015" class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf</a>." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Rich P, Feldman S, Vender R, Ortonne JP, Rustin M, et al. Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis. Poster P040 presentado en el Congress of the Psoriasis InternationalNetwork. Paríes, Jul 2010." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Kimball A, Goffe B, Bissonnette R, Yeilding N, Li S, et al. Efficacy of ustekinumab is sustained through 3 years of treatment for patients with moderate-to-severe psoriasis maintained on q12 week dosing based on body weight. Poster presentado en el Congress of the Psoriasis International Network; París, Francia. Jul 2010 Julio. Póster P044." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Gordon K, Lambert J, Gratton D, Baker D, Matheson R, et al. Sustained efficacy of ustekinumab for the treatment of moderate to severe psoriasis in initial responders continuing with maintenance therapy through year 3. Poster presentado en el Congress of the Psoriasis International Network; París, Francia. Jul 2010. Póster P046." ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ghislain PD, Poulin Y, Wasel N, Sofen H, Yeilding N, et al. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis. Poster presentado en el 19.° Congreso de la European Academy of Dermatology and Venereology; Gothenburg, Sweden. Oct 2010. Poster P589." ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sobell J, Hamilton T, Reich K, Ho V, Toth D, et al. Improved clinical response following a third dose of ustekinumab in psoriasis patients not achieving pasi75 at week 16: results from the phoenix 1 and phoenix 2 trials. Póster presentado en el Congress of the Psoriasis International Network; París. Jul 2010. Póster P045." ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Griffiths C, Strober B, Van der Kerkhof PCM, Ho V, Guzzo C, et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. Póster presentado en el Congreso de la EADV 2008. Paris. Póster P1336." ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Responses to ustekinumab in the anti-TNF agent-naïve vs. anti- TNF agent-exposed patients with psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Clemmensen" 1 => "M. Spon" 2 => "L. Skov" 3 => "C. Zachariae" 4 => "R. Gniadecki" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2010.03914.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "1037" "paginaFinal" => "1040" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21108668" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Jiménez Puya R, Salido Vallejo R, Gómez García F, Casas Asunción E, Vélez García-Nieto A, Moreno Giménez JC. Efficacy and safety of ustekinumab in the treatment of moderate and severe psoriatic patients: an open-label study. Póster presentado en el Summer Meeting de la AAD 2010, Chicago. Póster 2330." ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700042?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 9 | 12 | 21 |
| 2024 Octubre | 43 | 37 | 80 |
| 2024 Septiembre | 55 | 28 | 83 |
| 2024 Agosto | 51 | 55 | 106 |
| 2024 Julio | 72 | 27 | 99 |
| 2024 Junio | 58 | 51 | 109 |
| 2024 Mayo | 49 | 31 | 80 |
| 2024 Abril | 44 | 36 | 80 |
| 2024 Marzo | 45 | 37 | 82 |
| 2024 Febrero | 30 | 33 | 63 |
| 2024 Enero | 23 | 23 | 46 |
| 2023 Diciembre | 19 | 14 | 33 |
| 2023 Noviembre | 23 | 26 | 49 |
| 2023 Octubre | 13 | 9 | 22 |
| 2023 Septiembre | 37 | 35 | 72 |
| 2023 Agosto | 23 | 23 | 46 |
| 2023 Julio | 33 | 30 | 63 |
| 2023 Junio | 27 | 28 | 55 |
| 2023 Mayo | 10 | 8 | 18 |
| 2023 Abril | 18 | 13 | 31 |
| 2023 Marzo | 19 | 20 | 39 |
| 2023 Febrero | 15 | 18 | 33 |
| 2023 Enero | 17 | 29 | 46 |
| 2022 Diciembre | 30 | 26 | 56 |
| 2022 Noviembre | 31 | 28 | 59 |
| 2022 Octubre | 35 | 27 | 62 |
| 2022 Septiembre | 21 | 30 | 51 |
| 2022 Agosto | 42 | 37 | 79 |
| 2022 Julio | 33 | 35 | 68 |
| 2022 Junio | 20 | 25 | 45 |
| 2022 Mayo | 36 | 43 | 79 |
| 2022 Abril | 31 | 29 | 60 |
| 2022 Marzo | 35 | 50 | 85 |
| 2022 Febrero | 17 | 26 | 43 |
| 2022 Enero | 20 | 41 | 61 |
| 2021 Diciembre | 29 | 49 | 78 |
| 2021 Noviembre | 25 | 47 | 72 |
| 2021 Octubre | 34 | 49 | 83 |
| 2021 Septiembre | 22 | 39 | 61 |
| 2021 Agosto | 37 | 34 | 71 |
| 2021 Julio | 24 | 31 | 55 |
| 2021 Junio | 21 | 41 | 62 |
| 2021 Mayo | 23 | 46 | 69 |
| 2021 Abril | 52 | 55 | 107 |
| 2021 Marzo | 30 | 38 | 68 |
| 2021 Febrero | 34 | 24 | 58 |
| 2021 Enero | 17 | 16 | 33 |
| 2020 Diciembre | 23 | 19 | 42 |
| 2020 Noviembre | 29 | 15 | 44 |
| 2020 Octubre | 17 | 14 | 31 |
| 2020 Septiembre | 16 | 8 | 24 |
| 2020 Agosto | 28 | 12 | 40 |
| 2020 Julio | 22 | 17 | 39 |
| 2020 Junio | 17 | 22 | 39 |
| 2020 Mayo | 22 | 21 | 43 |
| 2020 Abril | 19 | 21 | 40 |
| 2020 Marzo | 22 | 24 | 46 |
| 2020 Febrero | 1 | 3 | 4 |
| 2019 Diciembre | 0 | 1 | 1 |
| 2019 Noviembre | 0 | 2 | 2 |
| 2019 Octubre | 0 | 1 | 1 |
| 2019 Septiembre | 0 | 3 | 3 |
| 2019 Julio | 0 | 2 | 2 |
| 2019 Junio | 0 | 3 | 3 |
| 2019 Mayo | 1 | 12 | 13 |
| 2019 Febrero | 0 | 1 | 1 |
| 2019 Enero | 0 | 1 | 1 |
| 2018 Diciembre | 0 | 3 | 3 |
| 2018 Noviembre | 0 | 7 | 7 |
| 2018 Octubre | 0 | 1 | 1 |
| 2018 Septiembre | 1 | 0 | 1 |
| 2018 Marzo | 2 | 0 | 2 |
| 2018 Febrero | 54 | 5 | 59 |
| 2018 Enero | 42 | 3 | 45 |
| 2017 Diciembre | 40 | 10 | 50 |
| 2017 Noviembre | 35 | 4 | 39 |
| 2017 Octubre | 30 | 6 | 36 |
| 2017 Septiembre | 22 | 5 | 27 |
| 2017 Agosto | 48 | 6 | 54 |
| 2017 Julio | 43 | 6 | 49 |
| 2017 Junio | 56 | 6 | 62 |
| 2017 Mayo | 40 | 11 | 51 |
| 2017 Abril | 51 | 8 | 59 |
| 2017 Marzo | 26 | 16 | 42 |
| 2017 Febrero | 33 | 5 | 38 |
| 2017 Enero | 35 | 8 | 43 |
| 2016 Diciembre | 35 | 6 | 41 |
| 2016 Noviembre | 54 | 7 | 61 |
| 2016 Octubre | 54 | 8 | 62 |
| 2016 Septiembre | 53 | 10 | 63 |
| 2016 Agosto | 60 | 13 | 73 |
| 2016 Julio | 31 | 7 | 38 |
| 2016 Mayo | 0 | 11 | 11 |
| 2016 Abril | 1 | 0 | 1 |
| 2016 Febrero | 0 | 3 | 3 |
| 2016 Enero | 0 | 18 | 18 |
| 2015 Diciembre | 0 | 18 | 18 |
| 2015 Noviembre | 8 | 12 | 20 |
| 2015 Octubre | 2 | 7 | 9 |
| 2015 Septiembre | 10 | 13 | 23 |
| 2015 Agosto | 2 | 7 | 9 |
| 2015 Julio | 37 | 3 | 40 |
| 2015 Junio | 26 | 4 | 30 |
| 2015 Mayo | 65 | 28 | 93 |
| 2015 Abril | 38 | 14 | 52 |
| 2015 Marzo | 39 | 9 | 48 |
| 2015 Febrero | 38 | 12 | 50 |
| 2015 Enero | 31 | 14 | 45 |
| 2014 Diciembre | 60 | 8 | 68 |
| 2014 Noviembre | 32 | 12 | 44 |
| 2014 Octubre | 35 | 25 | 60 |
| 2014 Agosto | 1 | 0 | 1 |
| 2014 Mayo | 1 | 0 | 1 |
| 2014 Enero | 2 | 2 | 4 |
| 2013 Octubre | 1 | 0 | 1 |
| 2013 Septiembre | 0 | 1 | 1 |
| 2013 Junio | 5 | 5 | 10 |
| 2013 Mayo | 1 | 1 | 2 |
| 2013 Abril | 1 | 1 | 2 |
| 2013 Marzo | 1 | 1 | 2 |
| 2013 Febrero | 0 | 1 | 1 |
| 2013 Enero | 0 | 1 | 1 |
Mostrar todo
